Eric Shore, MD
Pulmonary Disease · Hartford, CTNPI 1932203494
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 68.9% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2022 at $10,551 and has fallen 78.4% since, to $2,278 in 2025. Among pulmonary disease clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 792 payments — averaging $43.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$24K
- GSK$5K
- Boehringer Ingelheim$628
- Actelion Pharmaceuticals US, Inc.$457
- Insmed, Inc.$438
- Novartis$395
- plus $4K from 28 others
What the payments were for
- Speaking & faculty fees$20,00058%
- Travel & lodging$3061%
- Food & beverage$14,22341%
- Education$1300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 143 | $23,883 |
| GSK | 364 | $5,319 |
| Boehringer Ingelheim | 29 | $628 |
| Actelion Pharmaceuticals US, Inc. | 25 | $457 |
| Insmed, Inc. | 26 | $438 |
| Novartis | 25 | $395 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $358 |
| Regeneron Healthcare Solutions, Inc. | 14 | $316 |
| Mylan Specialty L.p. | 16 | $307 |
| Genentech USA, Inc. | 17 | $305 |
| Sunovion Pharmaceuticals Inc. | 16 | $213 |
| Amgen | 9 | $183 |
| Verona Pharma, Inc. | 8 | $182 |
| Sanofi | 8 | $175 |
| Jazz Pharmaceuticals Inc. | 8 | $169 |
| Mallinckrodt Hospital Products Inc. | 4 | $161 |
| Bayer | 2 | $138 |
| Covis Pharma GmbH | 7 | $123 |
| Circassia Inc. | 9 | $118 |
| Advanced Respiratory, Inc | 5 | $102 |
| Electromed, Inc. | 7 | $92 |
| Baxter Healthcare | 4 | $79 |
| Grifols USA, LLC | 4 | $78 |
| Philips North America LLC | 4 | $65 |
| Viatris Specialty LLC | 4 | $64 |
| Merck | 3 | $53 |
| Mallinckrodt Enterprises LLC | 3 | $45 |
| Shire North American Group Inc | 2 | $43 |
| Johnson & Johnson(2 entities) | 4 | $42 |
| Harmony Biosciences LLC | 1 | $36 |
| AbbVie | 2 | $35 |
| Lilly USA, LLC | 1 | $24 |
| La Jolla Pharmaceutical Company | 1 | $18 |
| Inogen, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$12,571
- BREZTRI AEROSPHERE$8,892
- FASENRA$746
- TEZSPIRE$391
- AIRSUPRA$266
- FARXIGA$253
- BEVESPI AEROSPHERE$129
- Adempas$126
- SYMBICORT$101
How this compares
$34,659 in reported general payments places this provider in the 90th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 720 | $656,218 |
| OfevNintedanib Esylate | 11 | $146,991 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 224 | $140,572 |
| TezspireTezepelumab-Ekko | 31 | $139,324 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 161 | $136,419 |
| Bosentan | 25 | $115,484 |
| Breo ElliptaFluticasone/Vilanterol | 198 | $113,850 |
| Spiriva RespimatTiotropium Bromide | 96 | $71,834 |
| XolairOmalizumab | 15 | $69,924 |
| Dupixent PenDupilumab | 16 | $64,321 |
| SymbicortBudesonide/Formoterol Fumarate | 153 | $44,360 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 72 | $43,835 |
| Arnuity ElliptaFluticasone Furoate | 104 | $34,733 |
| AlvescoCiclesonide | 68 | $29,446 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $18,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $5,319 | $964,3571,284 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler | $23,883 | $344,708393 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat, Striverdi Respimat | $628 | $279,289214 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $457 | $115,48425 claims |
| Covis Pharma GmbHAlvesco | $123 | $29,44668 claims |
| MerckDulera | $53 | $8,69022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in Hartford
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Jeffrey NascimentoHartford$213K
- Daniel GerardiHartford$156K
- James PopeHartford$125K
- Anil MaggeHartford$74K
- Francoise RouxHartford$39K
- John RussomannoHartford$18K
- Meredith HolubHartford$14K
- Jordan PownerHartford$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.